Market Overview
During the 24‑hour period concluding at 11:33 PM Central Europe on Friday, 23 November, Essity Aktiebolag (ESSITY‑A.ST) registered a modest decline of 0.36 %. The share price presently trades at SEK 275.5 on major exchanges, against a backdrop of a market capitalization of SEK 183.9 bn and a trading volume of approximately SEK 1.9 mn in the previous day. The 200‑day simple moving average sits at SEK 265.54, indicating a slight upside bias for the near term. Over the past year, the stock has climbed 3.38 % from its position at the month‑end, while its 52‑week high of SEK 292.5 (recorded on 24 February 2026) and low of SEK 239.5 (27 March 2026) frame the current price range.
Recent Earnings Review
Essity’s third‑quarter report revealed a 12 % year‑on‑year decline in profit to SEK 2.35 bn, despite modest sales growth. The board highlighted:
- Robust cash flow and stable volumes across its consumer tissue and professional hygiene segments.
- Ongoing cost‑saving initiatives that have begun to offset escalating raw‑material and energy expenses.
- Price‑increase strategy implemented to neutralise input cost inflation.
- Strategic reassessment of the Consumer Tissue division, with a potential carve‑out or continued integration under consideration.
- Acquisition of Kenvue’s feminine‑care business in Brazil, slated for completion in Q2 2027.
Following the announcement, the share price experienced a marginal uptick in early trading, reflecting a measured market reaction to the mixed outlook.
Peer Performance Snapshot
| Stock | % Move | Current Price | Market Cap | P/E | Key Highlights |
|---|---|---|---|---|---|
| Tele2‑B (TEL2‑A.ST) | –1.23 % | SEK 156 | SEK 110.8 bn | 10.99 | Positive sentiment driven by broader market balance; no material corporate actions reported. |
| Nibe Industrier‑B (NIBE‑B.ST) | +0.66 % | SEK 44.4 | SEK 89.3 bn | 33.64 | Incremental upside, reflecting steady industrial demand. |
| Skanska‑B (SKA‑B.ST) | +1.15 % | SEK 270.7 | SEK 110.6 bn | 16.85 | Recent real‑estate deals in Gothenburg and Mölndal bolster portfolio diversification. |
| Securitas‑B (SECU‑B.ST) | +0.61 % | SEK 156.5 | SEK 94.3 bn | 17.04 | Third‑quarter earnings in line with forecasts; emphasis on North American tech‑led security. |
| Lundbergs‑B (LUND‑B.ST) | +0.88 % | SEK 564 | SEK 141.7 bn | 7.66 | Consistent performance with a low P/E, indicating valuation upside. |
Strategic Outlook
Essity’s forward‑looking strategy hinges on balancing cost efficiencies with disciplined pricing while pursuing strategic acquisitions that align with its core competencies. The pending Brazilian acquisition is expected to enhance geographic diversification and tap into high‑growth markets in Latin America. Meanwhile, the ongoing review of the Consumer Tissue segment signals a potential shift toward higher‑margin, differentiated products or a focused portfolio that could unlock shareholder value.
Analysts project that, should the company sustain its cash‑flow resilience and complete the Brazilian acquisition on schedule, Essity could realign its growth targets and return to a trajectory of profitable expansion by the end of 2027. Investors will closely monitor the outcomes of the strategic review and the integration of the new acquisition, as these decisions will materially influence the company’s earnings profile and market valuation.
The information presented is based on the latest trading data and corporate disclosures as of 23 November 2026.
